[go: up one dir, main page]

CL2017001090A1 - Heterodimeric immunoglobulins of redirection of t-cells cd3 / cd38 and their production methods - Google Patents

Heterodimeric immunoglobulins of redirection of t-cells cd3 / cd38 and their production methods

Info

Publication number
CL2017001090A1
CL2017001090A1 CL2017001090A CL2017001090A CL2017001090A1 CL 2017001090 A1 CL2017001090 A1 CL 2017001090A1 CL 2017001090 A CL2017001090 A CL 2017001090A CL 2017001090 A CL2017001090 A CL 2017001090A CL 2017001090 A1 CL2017001090 A1 CL 2017001090A1
Authority
CL
Chile
Prior art keywords
redirection
cells
production methods
heterodimeric immunoglobulins
human
Prior art date
Application number
CL2017001090A
Other languages
Spanish (es)
Inventor
Rami Lissilaa
Romain Ollier
Samuel Hou
Darko Skegro
Jonathan Back
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2014/073738 external-priority patent/WO2015063339A1/en
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of CL2017001090A1 publication Critical patent/CL2017001090A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A INMUNOGLOBULINAS HETERO-DIMERICAS QUE DIRIGEN UN COMPONENTE DEL ANTIGUO CD3 HUMANO Y UN COMPONENTE DEL ANTÍGENO CD38 HUMANO Y A MÉTODOS PARA FABRICAR EL MISMO; LA PRESENTE INVENCIÓN TAMBIÉN SE REFIERE A ANTICUERPOS QUE SE UNEN AL ANTÍGENO CD38 HUMANO Y SUS DERIVADOS PARA USARSE COMO REACTIVOS TERAPÉUTICOS O DE DIAGNOSTICO Y MÉTODOS PARA FABRICARLOS.</p><p> THIS INVENTION REFERS TO HETERO-DIMERIC IMMUNOGLOBULINES THAT DIRECT A COMPONENT OF THE OLD HUMAN CD3 AND A COMPONENT OF THE HUMAN CD38 ANTIGEN AND METHODS TO MANUFACTURE THE SAME; THIS INVENTION ALSO REFERS TO ANTIBODIES THAT JOIN THE HUMAN CD38 ANTIGEN AND ITS DERIVATIVES FOR USE AS THERAPEUTIC OR DIAGNOSTIC REAGENTS AND METHODS TO MANUFACTURE THEM. </p>

CL2017001090A 2014-11-04 2017-05-02 Heterodimeric immunoglobulins of redirection of t-cells cd3 / cd38 and their production methods CL2017001090A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2014/073738 WO2015063339A1 (en) 2013-11-04 2014-11-04 Production of t cell retargeting hetero-dimeric immunoglobulins
EP15167034 2015-05-08

Publications (1)

Publication Number Publication Date
CL2017001090A1 true CL2017001090A1 (en) 2018-01-05

Family

ID=53059011

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001090A CL2017001090A1 (en) 2014-11-04 2017-05-02 Heterodimeric immunoglobulins of redirection of t-cells cd3 / cd38 and their production methods

Country Status (20)

Country Link
EP (1) EP3215541A1 (en)
JP (3) JP2018501297A (en)
KR (1) KR102760422B1 (en)
CN (1) CN107207596A (en)
AU (1) AU2015341884B2 (en)
BR (1) BR112017009263A2 (en)
CA (1) CA2965745C (en)
CL (1) CL2017001090A1 (en)
CO (1) CO2017005240A2 (en)
EA (1) EA039658B1 (en)
HK (1) HK1244014A1 (en)
IL (1) IL251848A0 (en)
MA (1) MA40894A (en)
MX (1) MX2017005814A (en)
MY (1) MY186929A (en)
NZ (1) NZ732019A (en)
PE (1) PE20171041A1 (en)
PH (1) PH12017500819A1 (en)
SG (1) SG11201703313SA (en)
WO (1) WO2016071355A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11434302B2 (en) 2016-02-03 2022-09-06 Amgen Research (Munich) Gmbh Bispecific T cell engaging antibody constructs
US11447567B2 (en) 2015-07-31 2022-09-20 Amgen Research (Munich) Gmbh Antibody constructs for FLT3 and CD3
US11884720B2 (en) 2015-07-31 2024-01-30 Amgen Research (Munich) Gmbh Antibody constructs for MSLN and CD3
US12428491B2 (en) 2016-02-03 2025-09-30 Amgen Research (Munich) Gmbh PSMA and CD3 bispecific T cell engaging antibody constructs

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
HRP20191865T1 (en) 2013-01-14 2020-01-10 Xencor, Inc. Novel heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
CA2918795A1 (en) 2013-07-25 2015-01-29 Cytomx Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
BR112016009919A2 (en) 2013-11-04 2017-12-05 Glenmark Pharmaceuticals Sa hetero-dimeric immunoglobulin or fragment thereof and method for producing in vitro a hetero-dimeric immunoglobulin or fragment thereof
EP3954713A3 (en) 2014-03-28 2022-03-30 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
WO2016014974A2 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
EP3223907A2 (en) 2014-11-26 2017-10-04 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
CN116333153A (en) 2014-11-26 2023-06-27 森科股份有限公司 Heterodimeric antibodies that bind CD3 and tumor antigens
TWI744242B (en) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Antibody constructs for egfrviii and cd3
KR20180085800A (en) 2015-12-07 2018-07-27 젠코어 인코포레이티드 CD3 and heterodimeric antibodies that bind to PSMA
IL263542B2 (en) 2016-06-14 2024-10-01 Xencor Inc Bispecific checkpoint inhibitor antibodies
KR20190020341A (en) 2016-06-28 2019-02-28 젠코어 인코포레이티드 Heterozygous antibodies that bind to somatostatin receptor 2
AU2018259039A1 (en) * 2017-04-24 2019-11-07 Ichnos Sciences SA T cell redirecting bispecific antibodies for the treatment of EGFR positive cancers
US11319371B2 (en) * 2017-06-05 2022-05-03 Numab Therapeutics AG Anti-CD3 antibodies
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
JP7679196B2 (en) 2017-06-08 2025-05-19 ブラック ベルト セラピューティクス リミテッド CD38 regulatory antibody
CN110997722B (en) 2017-06-08 2023-09-26 黑带医疗有限公司 CD38 modulating antibodies
UY37757A (en) * 2017-08-10 2018-11-30 Grifols Diagnostic Solutions Inc COMPOSITIONS, PROCEDURES AND / OR KITS THAT INCLUDE AN EXTRACELLULAR DOMAIN OF RECOMBINANT HUMAN CD38
US11542338B2 (en) 2017-08-16 2023-01-03 Black Belt Therapeutics Limited CD38 modulating antibody
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Multispecific molecules that bind to bcma and uses thereof
CA3072296A1 (en) 2017-08-16 2019-02-21 Black Belt Therapeutics Limited Cd38 antibody
CN111032693B (en) 2017-08-16 2023-09-26 黑带医疗有限公司 CD38 modulating antibodies
IL321773A (en) 2017-10-14 2025-08-01 Cytomx Therapeutics Inc Activatable antibodies and method for their preparation
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
CN112469477A (en) 2018-04-04 2021-03-09 Xencor股份有限公司 Heterodimeric antibodies binding to fibroblast activation proteins
EP3856347A1 (en) * 2018-09-25 2021-08-04 Ichnos Sciences SA Antibody quantification in biological samples
KR102353568B1 (en) * 2018-11-14 2022-01-20 주식회사 헬릭스미스 Anti c-Met Antibody or Antigen binding fragment thereof with Improved Stability
EP3914616A1 (en) 2019-01-23 2021-12-01 Encefa Cd31 competitors and uses thereof
EP3938398A2 (en) * 2019-03-13 2022-01-19 Ichnos Sciences S.A. Non-consensus glycosylation of bispecific antibodies
JP7611171B2 (en) * 2019-05-23 2025-01-09 ベロスビオ・インコーポレイテッド Anti-ROR1/anti-CD3 bispecific binding molecule
US20220227887A1 (en) * 2019-06-11 2022-07-21 Ono Pharmaceutical Co., Ltd. Immunosuppressant
CN110551222B (en) * 2019-08-27 2023-06-06 重庆市畜牧科学院 A novel bifunctional antibody and its application
CN112538114B (en) * 2019-09-20 2025-05-02 上海普铭生物科技有限公司 Anti-human CD38 antibody and its application
TWI841790B (en) * 2019-09-30 2024-05-11 大陸商和鉑醫藥（上海）有限責任公司 Antibodies targeting CD3, bispecific antibodies and their uses
CN113493519B (en) * 2020-03-19 2022-12-27 浙江道尔生物科技有限公司 Fusion protein with remarkably prolonged half-life for treating ocular angiogenesis diseases
WO2021185001A1 (en) 2020-03-19 2021-09-23 深圳纽迪瑞科技开发有限公司 Strain sensing film, pressure sensor and hybrid strain sensing system
CN115803340A (en) * 2020-04-24 2023-03-14 纪念斯隆凯特琳癌症中心 anti-CD 3 antibodies and uses thereof
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
AU2021292231A1 (en) * 2020-06-17 2023-01-19 Y-Mabs Therapeutics, Inc. CD38 antibodies for the treatment of human diseases
KR102607909B1 (en) 2020-08-19 2023-12-01 젠코어 인코포레이티드 Anti-CD28 composition
JP2024511319A (en) 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Heterodimeric antibody that binds to CD3 and CLDN6
JP2024509274A (en) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Heterodimeric antibody that binds to CD3 and GPC3
US20250340637A1 (en) * 2021-08-04 2025-11-06 Abpro Corporation Cd3 targeting antibodies and uses thereof
CN118108852B (en) * 2023-11-23 2025-11-18 浙江大学 A monoclonal antibody against acetamiprid and its recombinant full-length IgG expression plasmid

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008504013A (en) * 2004-02-06 2008-02-14 モルフォシス・アクチェンゲゼルシャフト Anti-CD38 human antibody and use thereof
EA015584B1 (en) * 2005-03-23 2011-10-31 Генмаб А/С ANTIBODY TO CD38 PERSON AND ITS APPLICATION
JP5362359B2 (en) * 2005-10-12 2013-12-11 モルフォシス アーゲー Generation and profiling of fully human HuCALGOLD-derived therapeutic antibodies specific for human CD38
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
MX368932B (en) * 2009-06-26 2019-10-22 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format.
SI2522724T1 (en) * 2009-12-25 2020-07-31 Chuqai Seiyaku Kabushiki Kaisha Polypeptide modification method for purifying polypeptide multimers
EP2580243B1 (en) * 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
JOP20210044A1 (en) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co Anti-CD38 . antibody
SG10201602371VA (en) * 2011-03-25 2016-04-28 Glenmark Pharmaceuticals Sa Hetero-dimeric immunoglobulins
EP2900696A1 (en) * 2012-09-25 2015-08-05 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
DK2914302T3 (en) * 2012-11-05 2017-04-10 Morphosys Ag RADIOACTIVALLY MARKED ANTIBODY AND USES OF IT
BR112016009919A2 (en) * 2013-11-04 2017-12-05 Glenmark Pharmaceuticals Sa hetero-dimeric immunoglobulin or fragment thereof and method for producing in vitro a hetero-dimeric immunoglobulin or fragment thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11447567B2 (en) 2015-07-31 2022-09-20 Amgen Research (Munich) Gmbh Antibody constructs for FLT3 and CD3
US11884720B2 (en) 2015-07-31 2024-01-30 Amgen Research (Munich) Gmbh Antibody constructs for MSLN and CD3
US11434302B2 (en) 2016-02-03 2022-09-06 Amgen Research (Munich) Gmbh Bispecific T cell engaging antibody constructs
US12428491B2 (en) 2016-02-03 2025-09-30 Amgen Research (Munich) Gmbh PSMA and CD3 bispecific T cell engaging antibody constructs

Also Published As

Publication number Publication date
MY186929A (en) 2021-08-26
IL251848A0 (en) 2017-06-29
NZ732019A (en) 2022-07-29
EA039658B1 (en) 2022-02-22
PH12017500819A1 (en) 2017-10-02
JP2021184722A (en) 2021-12-09
PE20171041A1 (en) 2017-07-19
CA2965745C (en) 2023-12-05
AU2015341884B2 (en) 2020-09-17
WO2016071355A1 (en) 2016-05-12
JP2019214582A (en) 2019-12-19
AU2015341884A1 (en) 2017-06-08
MX2017005814A (en) 2017-08-02
JP2018501297A (en) 2018-01-18
BR112017009263A2 (en) 2018-01-30
EP3215541A1 (en) 2017-09-13
CA2965745A1 (en) 2016-05-12
JP7403505B2 (en) 2023-12-22
CO2017005240A2 (en) 2017-10-31
SG11201703313SA (en) 2017-05-30
EA201790961A1 (en) 2017-10-31
KR20170078831A (en) 2017-07-07
CN107207596A (en) 2017-09-26
MA40894A (en) 2017-09-12
KR102760422B1 (en) 2025-02-03
HK1244014A1 (en) 2018-07-27

Similar Documents

Publication Publication Date Title
CL2017001090A1 (en) Heterodimeric immunoglobulins of redirection of t-cells cd3 / cd38 and their production methods
CY1124993T1 (en) HETERODIMER ANTIBODIES THAT BIND CD3 AND CD20
CL2017001361A1 (en) Heterodimeric antibodies that bind to cd3 and cd38
ECSP17011657A (en) DRUG CONJUGATES WITH ANTI-CDH6 ANTIBODIES
MX2016009555A (en) Binding proteins and methods of use thereof.
CR20170511A (en) HETERODIMERIC ANTIBODIES THAT JOIN CD3 AND TUMOR ANTIGENS.
CO2017006740A2 (en) Anti-cd79b antibodies
MX2018015592A (en) INHIBITING ANTIBODIES OF BISPECIFIC CONTROL POINTS.
UY35399A (en) CONJUGATES OF DRUGS WITH ANTIBODIES
EP3186279C0 (en) ANTIBODY CONSTRUCTS FOR CDH19 AND CD3
MX384364B (en) ANTI-PD-L1 ANTIBODIES AND THEIR DIAGNOSTIC USES.
JO3791B1 (en) BMP6-targeted antibody compositions and methods
UY36905A (en) POLIOMAVIRUS NEUTRALIZING ANTIBODIES
CO2018013298A2 (en) Anti-gitr antibodies and their uses.
UY36942A (en) ANTIGEN UNION PROTEINS THAT ACTIVATE THE LEPTINE RECEIVER
MX2018003822A (en) Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use.
EA201691610A1 (en) ANTI-JAGGED1 ANTIBODIES AND METHODS OF APPLICATION
CY1125400T1 (en) NOVEL ANTI-HUMAN GPVI ANTIBODIES AND THEIR USES
CL2016001753A1 (en) Humanized monoclonal antibody that specifically binds to netrin-1, pharmaceutical compositions and uses of the antibody for cancer treatment
UY37683A (en) MONOCLONAL ANTIBODY ANTI-PD-L1 MONOCLONAL
CL2017000212A1 (en) Angiopoietin 4-like anti-protein antibodies and methods of use
AR101671A1 (en) ANTIBODIES ANTI PROTEIN SIMILAR TO ANGIOPOYETINA-4 (ANGPTL4) AND METHODS OF USE
CL2020000920A1 (en) Anti-il-5ra monoclonal antibody.
BR112018004733A2 (en) Bispecific human / a-beta transferrin receptor antibodies and methods of use
CR20170222A (en) HETERODIMERIC ANTIBODIES THAT JOIN CD3 AND TUMOR ANTIGENS